following a full submission:
budesonide/formoterol (Symbicort® Turbohaler®) is accepted for restricted use within NHSScotland.
Indication under review: As reliever therapy for adults and adolescents (12 years and older) with mild asthma.
SMC restriction: for use in patients who would otherwise receive low dose inhaled corticosteroid (ICS) maintenance therapy plus short-acting beta-2 adrenoceptor agonist (SABA) as needed.
Budesonide/formoterol used as needed was non-inferior to an ICS maintenance treatment plus a SABA used as needed for the annualised rate of severe asthma exacerbations, and it was superior to a SABA used as needed for the outcome of well-controlled asthma weeks.
Medicine details
- Medicine name:
- budesonide/formoterol (Symbicort)
- SMC ID:
- SMC2622
- Indication:
Symbicort Turbohaler 200/6 as reliever therapy for adults and adolescents ≥12 years with mild asthma
- Pharmaceutical company
- AstraZeneca UK Ltd
- BNF chapter
- Respiratory system
- Submission type
- Full
- Status
- Restricted
- Date advice published
- 13 May 2024